SNRPD3

Across TCGA pan-cancer cohorts, SNRPD3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SNRPD3 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SNRPD3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SNRPD3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

HNSC, LSCC, and LUAD are the cancer types where SNRPD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	IV	0.569	0.973	<.001	41	view →
LSCC	DFS	Median	II,III,IV	0.888	0.516	.001	27	view →
LUAD	DFS	Quartile	All	0.779	0.301	.013	19	view →
CCRCC	OS	Median	III,IV	0.133	0.989	.013	19	view →
GBM	OS	Quartile	All	0.610	0.431	.039	2	view →
PDAC	DFS	Tertile	III,IV	0.574	0.888	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SNRPD3–HNSC (DFS)

Open the HNSC breakdown →